Antibodies against Clostridium difficile
AssigneeEmergent Biosolutions Canada Inc.
InventorsJody Berry, Cory Nykiforuk, Darrell Johnstone, Joyee Antony George
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin B. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
Claims23
An isolated antibody or antigen-binding portion thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL),
- wherein the heavy chain variable region comprises three complementarity determining regions (CDRs), CDR1, CDR2, and CDR3, having the amino acid sequences set forth in SEQ ID NOs:
- 126, 127, and 128, respectively, or the amino acid sequences set forth in SEQ ID NOs:
- 110, 127, and 128, respectively, and
- wherein the light chain variable region comprises three CDRs, CDR1, CDR2, and CDR3, having the amino acid sequences set forth in SEQ ID NOs:
- 118, 119, and 120, respectively;
- and
- wherein the antibody or antigen-binding portion thereof specifically binds to Clostridium difficile(C. difficile) toxin B.
An isolated antibody heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 43, 109, 125, and 141,
- wherein an antibody or antigen-binding binding portion thereof comprising the heavy chain variable region and a light chain variable region comprising the amino acid sequence SEQ ID NO:
- 35, 101, 117, or 133, respectively, can specifically bind to C. difficile toxin B.
An isolated antibody light chain variable region, wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 35, 101, 117, or 133,
- wherein an antibody or antigen-binding binding portion thereof comprising the light chain variable region and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:
- 43, 109, 125, or 141, respectively, can specifically bind to C. difficile toxin B.
Dependencies are inferred from the claim text.